Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Predictive and Prognostic Value of Non-coding RNA in Breast Cancer

Version 1 : Received: 22 May 2022 / Approved: 25 May 2022 / Online: 25 May 2022 (05:09:11 CEST)

A peer-reviewed article of this Preprint also exists.

Sobhani, N.; Chahwan, R.; Roudi, R.; Morris, R.; Volinia, S.; Chai, D.; D’Angelo, A.; Generali, D. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer. Cancers 2022, 14, 2952. Sobhani, N.; Chahwan, R.; Roudi, R.; Morris, R.; Volinia, S.; Chai, D.; D’Angelo, A.; Generali, D. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer. Cancers 2022, 14, 2952.

Journal reference: Cancers 2022, 14, 2952
DOI: 10.3390/cancers14122952

Abstract

For decades since the central dogma, cancer biology research has been focusing on the involvement of genes encoding proteins. It has been not until more recent times that a new molecular class has been discovered, named non-coding RNA (ncRNA), which has been shown to play crucial roles in shaping the activity of cells. An extraordinary number of studies into shown that ncRNAs represent an extensive and prevalent group of RNAs, including both oncogenic or tumor suppressive molecules. Henceforth, various clinical trials involving ncRNAs as extra ordinary biomarkers or therapies have started to emerge. In this review, we will focus on the prognostic and diagnostic role of ncRNAs for breast cancer.

Keywords

noncoding RNA; biomarkers; breast cancer; prognostic; diagnostic

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.